MedCram’s December 2020 description identifies Roger Seheult as the contributor and Kyle Allred as the interviewer. The programme asked about vitamin D in both prevention and treatment while evidence on COVID-19 was still emerging.
Its references include an Israeli study comparing blood measurements with infection risk and a small hospital trial of calcifediol. Those sources address different stages, from susceptibility to a treatment question after admission.
Original sources
Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study
Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.
Publication details
Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study
"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study"
“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”.
Publication details
“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”
NICE guidance on vitamin D and COVID-19
NICE guidance on vitamin D and COVID-19 · UK clinical guidance, recommendation 4.12.1.
Publication details
NICE guidance on vitamin D and COVID-19 · UK clinical guidance, recommendation 4.12.1
